Alejandro Galindo Joins MannKind as Chief Commercial Officer
July 20 2020 - 9:00AM
MannKind Corporation (NASDAQ: MNKD) today
announced that effective August 4, 2020, Alejandro Galindo, M.B.A,
M.S., will be leading MannKind’s commercial operations as Chief
Commercial Officer. Mr. Galindo will report directly to Michael
Castagna, Chief Executive Officer and will serve on the company’s
executive leadership team.
“We are excited to welcome Alejandro to MannKind
during a critical period of growth. He is an exceptional addition
to our executive leadership team and will be a tremendous asset to
us as we continue to expand our commercial organization,” said Mr.
Castagna. “I’m confident that Alejandro’s strong leadership skills
and extensive experience in product development, global expansion,
diabetes, and distribution strategy will help position us for
success in the future.”
Mr. Galindo joins MannKind with an accomplished
track-record of over 25 years in the healthcare, energy, and
consumer industries. He spent the past six years at Medtronic as
Vice President and President of the Advanced Insulin Management
Business Unit, where he led a fast-paced, double-digit growth
global business within their diabetes division. Prior to Medtronic,
Mr. Galindo spent nine years at General Electric (GE) Healthcare in
a variety of leadership roles, leading emerging markets, strategic
corporate development and global supply chain operations. Prior to
joining GE’s Healthcare division, he spent eleven years in various
global leadership positions for the company’s energy and appliance
sectors, overseeing advanced manufacturing engineering and product
development. Mr. Galindo received a B.Sc. in Industrial &
Systems Engineering from Monterrey Institute of Technology, Mexico
and M.B.A. and M.S. degrees from Indiana University.
"I’m thrilled to join such an innovative company
that is committed to transforming the standard of care for
insulin-dependent diabetes and orphan lung diseases,” said Mr.
Galindo. “I know MannKind has a bright future ahead, and I look
forward driving the commercial strategy and expanding access to
novel treatment options for patients with unmet medical
needs.”
About MannKind
CorporationMannKind Corporation (NASDAQ: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diabetes and orphan lung diseases.
MannKind is currently commercializing Afrezza® (insulin human)
Inhalation Powder, the Company’s first FDA-approved product and the
only inhaled ultra rapid-acting mealtime insulin in the United
States, where it is available by prescription from pharmacies
nationwide. MannKind is headquartered in Westlake Village,
California, and has a state-of-the art manufacturing facility in
Danbury, Connecticut. The Company also employs field sales and
medical representatives across the U.S. For further information,
visit www.mannkindcorp.com.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
risks and uncertainties. Words such as "believes," "anticipates,"
"plans," "expects," "intends," "will," "goal," "potential" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based
upon MannKind's current expectations. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and
uncertainties detailed in MannKind's filings with
the SEC. For a discussion of these and other factors, please
refer to MannKind’s annual report on Form 10-K for the year
ended December 31, 2019 as well as MannKind’s other filings
with the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. All forward-looking statements are qualified
in their entirety by this cautionary statement,
and MannKind undertakes no obligation to revise or update
any forward-looking statements to reflect events or circumstances
after the date of this press release.
Company
Contact:818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024